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Cisplatin has been successfully used in combinational 
therapies for the treatment of numerous solid tumors, with 
spectacular cure rates (higher than 90%) for testicular can-
cer (1). The drug is able to be hydrolyzed in cellular media 
and interact with DNA nucleobases, causing nuclear (2) 
(for proliferative cells) and mitochondrial damage, and 
leading to apoptotic cell death, where oxidative stress (OS) 
and inflammation are also involved (3, 4). In addition, in-
teraction with other biomolecules, including proteins (5) 
or lipids (6), might contribute to the cytotoxic effect (7). 
Unfortunately, side effects such as nephrotoxicity can take 
place, with around 30% of the patients developing acute 
kidney injury (8), being the most limiting side effect to 
the drug administrable dose (1). Cisplatin particularly ac-
cumulates in the S3 segment of the proximal tubule (9), 
leading to cell death and renal dysfunction. In such non-
proliferative cells, OS [involving reactive oxygen species 
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generation and consequent damage of lipids, proteins, or 
DNA (10)], nitrosative stress, and mitochondrial damage 
are particularly involved, with extrinsic and intrinsic apop-
totic pathways taking place (3).
Numerous nephroprotective approaches based on dif-
ferent molecular targets have been tested in vivo and in 
vitro for cisplatin (1, 11). However, nephroprotection is 
often incomplete, and the possible effect on the cytotoxic-
ity of tumor cells is usually unclear (1). Cilastatin, a se-
lective inhibitor of renal dehydropeptidase-I (DHP-I), has 
been shown to act as an effective nephroprotector for cis-
platin in in vitro (12) and in vivo (9, 10) models without 
affecting the antitumor effect of the drug. Its ability to in-
hibit apoptosis and OS and to decrease inflammatory re-
sponse in renal proximal tubule epithelial cells (RPTECs) 
has been demonstrated (10, 12–15), although the com-
plete mechanism of nephroprotection of cilastatin is not 
completely understood.
Omics methodologies, including metallomics (16, 17), 
proteomics (18, 19), or metabolomics (20, 21) have shown 
a high potential for unraveling cisplatin mechanisms of 
toxicity (18), discovery of possible therapeutic targets for 
nephroprotection,  and  suggestion  of  new  biomarkers  of 
renal damage (22).
Aside from their structural roles, lipids can be involved 
in cell signaling and metabolism (23), but their levels 
can be altered as a consequence of pathological condi-
tions.  Lipid  peroxidation  in  kidney  is  increased  as  a 
consequence of cisplatin-induced OS (24). In addition, 
triglyceride and NEFA levels were found to be raised in 
kidney  extracts  during  cisplatin  treatment  (21).  Phos-
phatidylcholine (PC) levels were also altered in lysates 
from human embryonic kidney cells treated with cispla-
tin (25), whereas differences have been reported in the 
membrane phospholipid composition of sensitive and re-
sistant cells to cisplatin treatment (26). Other lipidomics 
studies have also suggested a connection of lipid abnor-
malities in plasma with chronic kidney disease (23) or dia-
betic nephropathy (27).
Direct mapping of intact biomolecules (28–31) on bio-
logical samples [e.g., 5–10 µm thick tissue sections or even 
cells (32, 33)] can be performed using MALDI mass spec-
trometry imaging (MALDI-MSI) (34). This technique pro-
vides high spatial resolutions (typically 10–50 µm) (30, 35) 
and offers unique molecular distribution information in 
tissue with quantitative possibilities (36). Previous works 
have demonstrated that different lipid distributions can 
be found in different renal compartments in the normal 
kidney (37, 38), which can be expected, considering the 
structural and functional differences found along the 
nephron. On the other hand, under certain nephropathies 
(39, 40) or during polycystic kidney disease (41), lipid al-
terations can be observed directly in tissue sections. Recent 
research also demonstrated that cisplatin treatment caused 
phospholipid distribution alterations in rat kidney sections, 
including PC, phosphatidylethanolamine (PE), phosphati-
dylserine (PS), phosphatidylglycerol (PG), phosphatidylino-
sitol (PI), phosphatidic acid (PA), or lysophospholipids 
(LPLs) (42). Therefore, this suggests MALDI-MSI as a 
potentially useful tool for identifying renal damage beyond 
traditional methods.
Herein, we have further investigated the nephroprotec-
tive effect of cilastatin in a cisplatin-treated rat model, with 
a special  focus  in kidney  lipid distribution. Moreover, we 
have explored the possibility of using MALDI-MSI as an al-
ternative tool for nephroprotection and nephrotoxicity 
evaluation in kidney sections with promising results.
MATERIALS AND METHODS
Chemicals
Cisplatin was obtained from Pharmacia Nostrum (Madrid, 
Spain). Cilastatin was kindly offered by Merck Sharp and Dohme 
S.A. (Madrid, Spain). Both drugs were dissolved in 0.9% NaCl 
solution (Braun Medical S.A, Barcelona, Spain) for administra-
tion. The 2,5-dihydroxybenzoic acid (DHB) and 9-aminoacrydine 
(9-AA), used as MALDI matrices, and methanol (MeOH), ace-
tonitrile (ACN), 2-propanol (iPrOH), and trifluoroacetic acid 
(TFA), used as matrix solvents, were all purchased from Sigma-
Aldrich (Steinheim, Germany).
Animals and tissue sections
Female, 7 week old Wistar rats (WKY, Criffa, Barcelona, Spain) 
were treated at the animal facilities of the Instituto de Investig-
ación Sanitaria Gregorio Marañón (IiSGM, Madrid, Spain). The 
animals were fed and provided water ad libitum and kept under 
controlled light (12 h light/dark cycle), temperature, and humid-
ity conditions. All the procedures were approved by the Ethics 
Committee on Animal Experimentation from the IiSGM, and ani-
mals were treated in accordance with Directive 2010/63/EU and 
of Spanish Royal Decree 53/2013 on the protection of animals 
used for experimentation and other scientific purposes.
Four groups of rats were administered treatments by intraperi-
toneal injection (i.p.) as previously described (9, 10): 1) control 
rats injected a 0.9% NaCl solution in the same doses and regimes 
of groups 3 and 4 (n = 4); 2) cilastatin-treated rats [150 mg·kg1 
of body weight (bw) per day, n = 4]; 3) cisplatin-treated rats 
(single dose of 5 mg·kg1 bw at day 0, i.p., n = 4); and 4) cisplatin 
(as in group 3) plus cilastatin (as in group 2) treated rats (n = 4). 
After 5 days of treatment, animals were anesthetized and eutha-
nized. Prior to the euthanization, urine from each animal was 
collected for 24 h in metabolic cages. Serum was obtained by cen-
trifugation of blood samples. Kidneys were perfused with saline 
solution at 4°C, removed, decapsulated, and wrapped in alumi-
num foil, followed by snap-freezing in liquid N2 and stored at 
80°C. Sagittal  sections of 5 or 10 µm thickness were obtained 
with a cryostat (Thermo Fisher Scientific, model no. HM525 NX) 
at 20°C, thaw-mounted onto Superfrost Plus slides (Thermo 
Fisher Scientific, Braunschweig, Germany), and stored at 80°C.
Histological studies
The  5  µm  sagittal  rat  kidney  sections  were  stained  with  
hematoxylin–eosin (HE) (Sigma-Aldrich). Microphotographs were 
taken from the sections  for histological examination using an 
inverted IX70 microscope (Olympus, Hamburg, Germany) with 
20× and 60× magnification.
Renal failure-indicating biochemical parameters
Blood urea nitrogen (BUN) and creatinine were determined 
in serum using a modular AutoAnalyzer Cobas 711 (Roche, Basel, 
Switzerland). Glomerular filtration rate (GFR) was calculated by 
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using creatinine clearance rate. The sulfosalicylic acid method 
(43) was used for total protein analysis in urine.
Immunohistochemistry
Immunohistochemistry was carried out on 5 µm tissue sections 
as  previously  described  (10).  Polyclonal  anti-Kidney  Injury 
Molecule-1 (anti-KIM-1) (R&D Systems; dilution 1:20) and 
monoclonal anti-4-hydroxy-2-nonenal (anti-4-HNE) (Oxis Inter-
national Inc., Foster City, CA; dilution 1:75) were used as primary 
antibodies. The specificity of the antibodies was verified by con-
trols  lacking  the  primary  antibody,  producing  no  background. 
The surface area labeled by the antibodies was evaluated by quan-
titative image analysis (10).
Apoptosis detection
DNA fragmentation, an apoptosis indicator, was determined by 
TUNEL assay in 5 µm kidney tissue sections using a Fluorescein 
FragEL DNA Fragmentation Detection Kit (Calbiochem, San 
Diego, CA), as previously described (10). A confocal microscope 
(Leica-SP2, Leica Microsystems, Heidelberg, Germany) was em-
ployed for visualization of TUNEL-positive cells. For each renal 
section, cells undergoing apoptosis were quantified in a blinded 
manner by counting all positive apoptotic cells in eight nonover-
lapping random fields viewed at 20× magnification.
MALDI-MSI
First, 10 µm kidney slices were thawed inside a desiccator. Ei-
ther DHB (60 mg·ml1 in 70% MeOH with 0.1% TFA) or 9-AA 
(60 mg·ml1 in 70% iPrOH/ACN (60:40) with 0.1% TFA) were 
used as matrices for positive or negative ion mode analysis, respec-
tively. Each matrix was applied on the tissues with an airbrush 
in 15 cycles comprising deposition for 20 s followed by drying for 
40 s, as previously described (42).
Data were acquired using a MALDI LTQ Orbitrap XL Pro mass 
spectrometer (Thermo Scientific, San José, CA), and laser inten-
sity was adjusted to 22.5 µJ for DHB and 25–30 µJ for 9-AA. Imag-
ing was performed in rastering mode, with a spatial resolution of 
100 µm. Mass spectra were registered in full-scan mode at m/z 
200–2,000 and 2 microscans per step either in positive or negative 
ion mode, with a 60,000 mass resolution on the Fourier Trans-
form MS analyzer. Data processing was carried out using Image-
Quest software (Thermo Scientific), MS images were extracted 
with 0.008 Da tolerance, and total ion current (TIC) normaliza-
tion was applied. MSI raw files were converted to imzML (44) us-
ing ImageQuest and further processed with MSiReader (45) for 
tissue comparison in substructural renal features. Data were ex-
tracted from six regions of interest (ROIs) per treatment type and 
substructure, each ROI comprising 200 data points. For exact 
mass identification, a database search in LipidMaps (46) and Lip-
idBlast (47) was performed with a mass tolerance of 5 ppm. Lipid 
identification was assisted with MS/MS fragmentation experi-
ments carried out in the ion trap by collisionally induced dissocia-
tion at 35% energy.
Statistical analysis
Quantitative variables were expressed as mean ± SEM. SPSS 
(Version 11.5; SPSS, Chicago, IL) was used for descriptive statis-
tics and evaluating statistical differences in variables between 
groups by ANOVA. Lipid variables from ROIs were compared be-
tween groups using Mann–Whitney and Kruskal–Wallis tests with 
SPSS 11.5. A significance level of 0.05 was employed for iden-
tifying statistically significant differences. False discovery rate 
(FDR) correction was performed using the Benjamini–Hochberg 
method. Multivariate analysis, including principal component 
analysis (PCA) and partial least squares discriminant analysis 
(PLS-DA), was performed using MetaboAnalyst (Version 3.0) 
(48). Lipid data extracted from MSiReader (45) were TIC-
normalized, log-transformed, and pareto-scaled prior to multi-
variate analysis.
Lipid nomenclature
The nomenclature for lipids proposed by the LipidMaps con-
sortium (46) was employed. Briefly, glycerophospholipids [PE, PC, 
PS, PI, PI phosphate (PIP), phosphatidyl inositol ceramide (PI-Cer), 
PG, lysophosphatidylethanolamine (LPE), lysophosphatidylcho-
line (LPC), lysophosphatidylserine (LPS), lysophosphatidylino-
sitol (LPI), lysophosphatidylglycerol (LPG), PA, and cardiolipins 
(CLs)] are designated followed by (W:X), W being the total acyl 
chains length and X the total amount of double bonds. Sphingo-
lipids (SM and sulfatides, including SM2a and SM4s-), are followed 
by (Y:Z), where Y is the length of the sphingosine-bound acyl chain 
and Z is the total amount of double bonds in the chain. Alkyl ether 
linkage and (1Z)-alkenyl ether, are designated by “O-” and “P-”, re-
spectively. Finally, “h”, “d,” and “t” indicate 1-hydroxy, 1,3 dihydroxy, 
and 1,3,4-trihydroxy, respectively, sphingolipid long-chain bases.
RESULTS
Cilastatin attenuation of cisplatin-induced bw loss
Supplemental Table S1 shows how cisplatin treatment 
leads to a significant increase in rat bw loss compared with 
control rats. Importantly, cilastatin cotreatment with cispla-
tin partially attenuated the effect exerted by the latter. 
Cilastatin alone did not have any impact on rat bw with re-
spect to control animals.
Cilastatin effect on classical indicators of cisplatin-
induced renal injury
Renal function in treated animals was assessed with classi-
cal biochemical indicators. Serum creatinine, BUN, urinary 
volume, and urinary proteins (all of them significantly in-
creased during cisplatin treatment with respect to control 
animals) were decreased to control levels in the presence of 
cilastatin, as shown in Table 1. GFR was decreased during 
cisplatin treatment with respect to control samples, con-
firming renal damage, whereas cotreatment with cilastatin 
prevented this effect. On the other hand, treatment with 
only cilastatin did not affect any of the above parameters.
Cilastatin protects against cisplatin-induced morphological 
renal lesions
Histology was examined in HE-stained sections in search 
of morphological alterations related to renal damage. 
Figure 1 shows a normal morphology in control and 
cilastatin-treated renal sections. However, cisplatin treat-
ment displayed clear signs of nephrotoxicity in the proxi-
mal renal tubules, including tubule swelling, cell debris 
detachment, hyaline casts accumulation, or loss of brush 
border membrane (Fig. 1C, E, G), all of them being signifi-
cantly prevented with the use of cilastatin (Fig. 1, F, H).
Cilastatin decreases expression of cisplatin-induced early 
renal damage markers
KIM-1  has  been  described  as  a  protein  biomarker  of 
early renal damage measurable in tissue and urine (49). 
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KIM-1 expression was measured in kidney sections by im-
munostaining, as shown in Fig. 1. KIM-1 was significantly 
overexpressed in proximal tubule cells, mainly in the corti-
comedullary junction, renal cortex, and outer medulla of 
the cisplatin-treated group (Fig. 1K, M), in comparison 
with the control group (Fig. 1I). This was significantly ame-
liorated when cilastatin was coadministered with cisplatin 
(Fig. 1L, N), whereas cilastatin alone (Fig. 1J) did not have 
any effect on KIM-1 expression compared with the control 
tissue (Fig. 1I).
Cilastatin attenuates cisplatin-induced apoptosis
Apoptosis was evaluated by TUNEL in kidney sections, as 
shown in supplemental Fig. S1. Cisplatin turned out to in-
crease the number of TUNEL-positive cells (supplemental 
Fig. S1C) with respect to control samples (supplemental 
Fig. S1A), as quantified in supplemental Fig. S1E. Treatment 
with cilastatin significantly decreased the number of TUNEL-
positive cells when coadministered with cisplatin (supple-
mental Fig. S1D), whereas cilastatin itself (supplemental 
Fig. S1B) did not exert any relevant effect compared with 
control kidney, as can be seen in supplemental Fig. S1E.
Cilastatin reduces lipid peroxidation associated to 
cisplatin treatment
The 4-HNE is a product of FA oxidation and is consid-
ered an OS biomarker (50). Lipid peroxidation was de-
termined by 4-HNE immunohistochemical detection in 
kidney sections. Cisplatin treatment resulted in increased 
4-HNE staining in kidney (supplemental Fig. S2C) with re-
spect to control tissue (supplemental Fig. S2A). Again, 
cotreatment with cilastatin prevented cisplatin-induced in-
crease of 4-HNE (supplemental Fig. S2D), whereas cilas-
tatin alone did not modify 4-HNE production (supplemen-
tal Fig. S2B) compared with the control tissue, as shown in 
supplemental Fig. S2E.
Cilastatin diminishes cisplatin-induced alterations of renal 
lipids
The distribution of certain renal lipids was previously 
found to be altered under treatment with cisplatin in a rat 
model (42). In order to evaluate the countereffect of cilas-
tatin on cisplatin-induced lipid alterations, images for 
lipids were produced in positive and negative mode by 
MALDI-MSI in kidney sections from rats either untreated 
or treated with cisplatin, cilastatin, or the combination of 
the latter two. Figure 2 summarizes the effect of cisplatin 
treatment on the renal distribution of 76 lipid species (in-
cluding 13 newly found CLs decreased by cisplatin) and 
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), 
along with the protective effect of cilastatin. Supplemental 
Table S2 presents the complete renal lipid distribution for 
the four groups of samples analyzed with both ionization 
modes, along with lipid identification data. Additionally, 
Fig. 3 shows images for selected structural lipids detected 
in positive mode, including PC(34:2), PE(38:7), PC(34:0), 
PC(36:5), and PC(40:6) species, whereas Fig. 4 shows im-
ages for negative mode-detected lipids, including PA(36:4), 
LPI(18:0), PI(38:4), PS(36:4), PI(36:2) CL(72:8), PG(34:1), 
or SM4 (t18:0, h24:1). The HE-stained parallel slices and 
the local lipid intensities found in the cortex and outer me-
dulla for the four types of samples are also displayed in 
Figs. 3 and 4. As shown in supplemental Table S2, and il-
lustrated in Figs. 2–4, in contrast to the cisplatin-induced 
effect observed, coadministration of cilastatin along with 
cisplatin attenuated these lipid alterations either totally 
(for 31 species, where lipid distributions were comparable 
to those of control kidney samples) or partially (for 39 lipid 
species). Only in the case of seven lipid species [PI(40:7), 
SM4(t18:0, h24:1), CL(70:6), CL(70:7), CL(70:8), CL(70:9), 
and CL(72:10)], no significant differences in renal distribu-
tion were observed between cisplatin and cisplatin+cilastatin-
treated groups, and therefore no recovery was observed. 
On the other hand, treatment with cilastatin alone led to 
no relevant changes in the main renal lipid distribution in 
comparison to control samples, as shown in Figs. 3 and 4 
and supplemental Table S2.
Figure 5 shows a lipid class-based analysis of the effects 
of cisplatin on renal lipids. PI and PC are the main lipid 
classes increasing in renal cortex due to cisplatin treat-
ment, followed by LPG, PG, and PS (Fig. 5A). Furthermore, 
PC is the main lipid type displaced from cortex to medulla 
after cisplatin treatment (Fig. 5B), whereas PI, LPG, LPI, 
PS, and PG are the main lipids that are simultaneously in-
creased in cortex and medulla during cisplatin treatment 
(Fig. 5C). Moreover, Fig. 5D, E shows the effect of cisplatin 
on the amount of double bonds found in renal cortex lip-
ids, with the overall trend to reduce the degree of PUFA-
containing phospholipids. Finally, Fig. 5F, G displays the 
effect of cilastatin on cisplatin-induced changes on cortex 
and medulla lipids, according to their class type, showing a 
tendency of recovery of control lipid distribution for most 
of the lipid classes.
Discrimination of cisplatin-treated and cilastatin-protected 
kidney based on multivariate analysis of cortical and 
medullary lipids
PCA performed on cortex and outer medulla lipids 
found in positive (Fig. 6B, D) and negative ionization mode 
TABLE 1. Protective effect of cilastatin of renal function under cisplatin treatment
Groups SCreat (mg/dl) BUN (mg/dl) GFR (ml/min/100 g) UVol (ml/24 h) UProt (mg/24 h)
Control 0.44 ± 0.01 16.9 ± 0.9 0.46 ± 0.06 7 ± 2 1.4 ± 0.6
Control + cilastatin 0.42 ± 0.07 17 ± 1 0.52 ± 0.08 10 ± 1 1.65 ± 0.07
Cisplatin 3 ± 1a 100 ± 30a 0.16 ± 0.06a 24 ± 2a 6 ± 1b
Cisplatin+ cilastatin 0.6 ± 0.1 14 ± 2 0.40 ± 0.04 10 ± 1 1.6 ± 0.3
Results are expressed as mean ± SEM. SCreat, serum creatinine; UProt, urinary protein; UVol, urinary volume.aP < 0.05 versus other groups (in each column).
bP < 0.005 versus other groups (in this column).
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(Fig. 6A, C) led to a clear group separation of cisplatin-
treated  kidney  with  respect  to  control,  cilastatin-treated, 
and cisplatin+cilastatin-treated groups, the latter resem-
bling more control groups. PLS-DA led to analogous group 
discrimination for cortex and outer medulla lipids, as 
shown in supplemental Figs. S3 and S4, respectively. As can 
be seen, the group treated both with cisplatin and cilastatin 
tended to completely separate from the rest of the groups 
in the PLS-DA. Variance in projection (VIP) scores for PLS-
DA of the four groups are also presented in supplemental 
Figs. S3 and S4 for cortex and medulla lipids, respectively, 
indicating relevant features leading to groups separation 
with a 1.0 cut-off. Good prediction models were obtained 
for all cases, with R2 and Q2 higher than 0.9, considering 
three components.
Separate PLS-DA of cisplatin versus control groups are 
presented for lipids in positive (Fig. 6E, F) and negative 
(supplemental Fig. S5A, B) ionization modes for cortex 
and medulla, respectively. According to the correspond-
ing VIP scores (Fig. 6G, H; supplemental Fig. S5C, D), 
PC(42:10), PC(36:3), PC(40:7), PC(34:2), and PI(38:4) 
in cortex and PG(37:7), PC(38:4), PE(38:7), PC(38:4), 
PC(40:6), PE(36:4), and LPC(18:0) in medulla are the pos-
itive lipids contributing the most to cisplatin discrimina-
tion with respect to the control group. In negative mode, 
PI-Cer(t44:0), PI(39:4), PG(34:1), PS(40:7), LPG(20:5), and 
Fig. 1.  Cilastatin prevents cisplatin-induced morphological lesions and reduces the expression of the early renal damage marker KIM-1. 
The 20× microscope images for HE-stained kidney sections for control (cortex) (A), control+cilastatin (cortex) (B), cisplatin (cortex, C; and 
medulla, E), cisplatin + cilastatin (cortex, D; and medulla, F). The 60× magnified images are displayed in for cortex areas in cisplatin (G) 
and cisplatin+cilastatin (H). Cisplatin-induced signs of damage are depicted as follows: hyaline casts are indicated with arrows; # denotes cell 
debris detachment; and * represents loss of intercellular junctions. D, H: Scale bars represent 100 (D) or 25 (H) µm. Microscopy images for 
immunostained kidney sections for KIM-1 detection visualized at 20× are compared for control (I), control + cilastatin (J), cisplatin (K), and 
cilastatin + cisplatin (L). Whole kidney images for cisplatin-treated (M) and cilastatin + cisplatin-treated (N) rats. L: Scale bar represents 
50 µm size. O: Quantitative results for KIM-1 staining are expressed as mean ± SEM; n = 4 animals per group. * P < 0.05 versus control and 
control+cilastatin groups; † P < 0.02 versus cisplatin group. 
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PI(38:4) in cortex and LPS(20:4), LPG(22:5), LPG(20:4), 
LPG(20:5), PIP(36:3), and CL(78:5) in medulla are the 
variables contributing the most to discriminating cisplatin 
from control groups.
MALDI imaging of lipids allows visualizing nephrotoxicity 
and nephroprotection effects
MALDI-MSI allows simultaneous acquisition of data for 
building distribution images for hundreds of lipid species 
in a tissue section. Combining information on multiple 
species could lead to a more reliable assessment of renal 
damage or nephroprotection in tissue. Figure 7 shows indi-
vidual renal distributions for [M-H]- ions for PA(36:1) at 
m/z 701.5145 and PI(34:0) at m/z 837.5529, along with 
merged images for both species for the four types of animal 
groups. Two clearly distinct patterns were observed for the 
samples either with no renal damage (control, Fig. 7A–C; 
cilastatin, Fig. 7D–F; and cilastatin coadministered with cis-
platin, Fig. 7J–L) or presenting cisplatin-induced acute kid-
ney injury (Fig. 7G–I). These differences were enhanced in 
the merged images for both lipids distribution.
DISCUSSION
Nephrotoxicity is a serious side effect of several thera-
pies, including cisplatin (51). Cisplatin is able to accumu-
late in RPTECs, leading to OS, nuclear and mitochondrial 
Fig. 2. Protective effect of cilastatin against cisplatin-induced alterations on cortical and medullary renal lipids. MALDI-MSI relative quan-
tification results are shown for 77 species (76 lipids), according to their lipid class, for control rat kidney versus cisplatin (Cis) or cisplatin+ 
cilastatin (CisCil)-treated kidney in cortex (C) and medulla (M). The effect of cisplatin and cilastatin with respect to control lipid levels (with 
FDR < 0.05) is presented with the following color code: red, decrease versus control; green, increase versus control; black, no change versus 
control; blue, total recovery versus control levels; light blue, partial recovery versus control levels. Control kidneys lipid location is presented 
with the following abbreviations: C, cortex; CM, corticomedullary junction; H, homogeneous distribution; IM, inner medulla; M, medulla 
(including OM and IM); OM, outer medulla; RC, renal column. * denotes kidney region with the highest lipid intensity, when present in 
several regions.
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damage, apoptotic (and also necrotic) cell death, and re-
nal failure (8). Cilastatin was recently shown to effectively 
protect against nephrotoxicity induced by cisplatin (10), 
vancomycin (13), cyclosporine A, and tacrolimus (52) and 
to enable restored renal function. As previously reported, 
cilastatin interacts with DHP-I located in the brush border 
lipid raft of RPTECs, thus inhibiting its enzymatic activity 
(53) and preventing any related transport or signaling 
based on vesicle internalization (13). Therefore, cilastatin 
can inhibit the extrinsic pathway of apoptosis and, to some 
extent, reduce luminal entry of drugs in DHP-I-bearing 
RPTECs without interfering with the pharmacological ef-
fect of cisplatin in target cells (12).
Consistent with our previous observations in a male rat 
model (10), we show that cilastatin protects against cisplatin-
induced renal damage in a female rat model, ameliorating 
the effects of cisplatin on weight loss and renal function 
(measured in terms of GFR, serum creatinine, and BUN) 
and preventing renal lesions. In contrast to results from 
other studies (54), this finding confirmed the toxic effect 
of cisplatin and the protective effect of cilastatin, regardless 
of the animal’s gender. The results of the TUNEL assay in 
tissue also supported this observation, with clearly dimin-
ished apoptotic cell death when cilastatin and cisplatin 
were coadministered, as compared with the tissues after 
treatment with cisplatin. Furthermore, KIM-1 staining in 
tissue made it possible to visualize and locate early renal 
damage caused by cisplatin in the renal cortex and outer 
medulla. This finding is in agreement with the fact that the 
S3 segment of the proximal tubule, the main focus of renal 
damage, is located in those same areas. Cotreatment of 
cisplatin with cilastatin revealed almost nondetectable 
Fig. 3. Cilastatin protects against cisplatin-induced lipid alterations: structural lipids (PC and PE) found in positive ion mode. HE-stained 
kidney sections images are displayed (A–D for control, control+cilastatin, cisplatin, and cisplatin+cilastatin, respectively) along with the de-
limited cortex, medulla, and corticomedullary  junction (CMJ) regions. Their respective MALDI-MSI images in positive-ion mode for se-
lected lipid distributions have been included below each HE image: PC(34:2) (E–H), PE(38:7) (I–L), PC(34:0) (M–P), PC(36:5) (Q–T), and 
PC(40:6) (U–X). Color-scale bar is shown for lipid images. Right: Bar charts for the local lipid intensities observed for the four groups in 
either  kidney  cortex or medulla  are displayed next  to  the  lipid distribution  images  for  each of  the  lipid  species  selected. Control  (1), 
control+cilastatin (2), cisplatin (3), and cisplatin+cilastatin (4) groups are represented in red, green, blue, and cyan, respectively. * FDR < 
0.05 versus all other groups; # FDR < 0.05 versus control group.
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Fig. 4.  Cilastatin protects against cisplatin-induced lipid alterations: lipids detected in negative ion mode. HE-stained kidney sections im-
ages are displayed (A–D for control, control+cilastatin, cisplatin, and cisplatin+cilastatin, respectively) along with the delimited cortex, me-
dulla, and corticomedullary junction (CMJ) regions. Their respective MALDI-MSI images in negative-ion mode for selected lipid distributions 
have been included below each HE image: PA(36:4), LPI(18:0), PI(38:4), PS(36:4), PI(36:2), CL(72:8), PG(34:1), and SM4(t18:0, h24:1). 
Color-scale bar is shown for lipid images. Right: Bar charts for the local lipid intensities observed for the four groups in either kidney cortex 
or medulla are displayed next to the lipid distribution images for each of the lipid species selected. Control (1), control+cilastatin (2), cispla-
tin (3), and cisplatin+cilastatin (4) groups are represented in red, green, blue, and cyan, respectively. * FDR < 0.05 versus all other groups; 
# FDR < 0.05 versus control group.
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expression of KIM-1, providing additional evidence on the 
nephroprotective effect of cilastatin. Moreover, signs of 
lipid peroxidation due to OS (based on 4-HNE detection) 
during treatment with cisplatin were not visible under pro-
tection with cilastatin.
Aside from causing lipid peroxidation, cisplatin was 
reported to modify the renal distribution of lipid spe-
cies in controls in a rat model (42) in regions of the 
kidney where damage  takes place,  suggesting a correla-
tion between the nephrotoxic effect exerted by the drug 
and the lipid changes induced (42). In this case, we stud-
ied the effect of cilastatin in 76 renal lipid species and 
UDP-GlcNAc, all of which were altered with cisplatin. 
This finding adds to previous results (42) with new, 
additional 13 CL species. To our knowledge,  this  is  the 
first time their effect has been visualized. Cilastatin fully 
Fig. 5. Effect of cisplatin on renal lipids distribution, according to lipid class and number of acyl-chain double bonds, and the protective 
effect of cilastatin. Percentage of renal species according to lipid class showing an increase in cortex (A), a displacement from cortex to 
medulla (B), and a simultaneous increase in cortex and medulla (C) after cisplatin (cisPt) treatment. D: Percentage of lipids increasing 
(open bars) and decreasing (filled bars) in renal cortex after cisplatin treatment according to the amount of double bounds in the acyl 
chains. E: Ratio of increased versus decreased lipids in cortex after cisplatin treatment, according to the amount of double bounds in the acyl 
chains. The restoring effect of cilastatin against cisplatin-induced changes according to lipid class is displayed in F and G for cortex and 
medulla, respectively.
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or partially restored most of the cisplatin-altered lipid 
levels.
Among structural lipids, PC and, to a lesser extent, PE 
are the most abundant species in membranes (55). PC is 
the lipid type that best differentiates between control and 
cisplatin-treated kidney, especially PC(42:10) (Fig. 6), and 
the lipid class with the second highest increase in renal cor-
tex in rats treated with cisplatin (Fig. 5A). Correlation with 
histology suggests that increased PC species in cortex might 
represent a regenerative cellular response after the ini-
tial cisplatin-induced damage. Moreover, cisplatin-induced 
proximal tubule cell damage leads to luminal release of 
apoptotic bodies with intact cell membranes, which can 
subsequently be trapped in the medulla by intratubular 
protein casts. This migration of fragments from damaged 
proximal tubule cells might explain why PC species are 
decreased in the cortex and increased in the medulla 
(Fig. 5B). Cilastatin, a specific ligand of proximal tubule 
cells that can block amplification of apoptosis, significantly 
restored most of the structural PC and PE lipids to control 
values in both the cortex and the medulla.
PI is the primary source of arachidonic acid [AA; 
FA(20:4)], which is released from the sn-2 position via the 
action of the enzyme phospholipase A2 (PLA2) (56, 57). 
The main PI species in kidney is PI(18:0/20:4), which be-
longs to the PI(38:4) family of isomers (55, 56, 58). In this 
case, several PI species were increased in either the cortex 
or the outer medulla after treatment with cisplatin. For in-
stance, PI(38:4), the most abundant PI species in both the 
medulla and the cortex, was found to be increased after 
treatment with cisplatin in both substructures, especially in 
the outer medulla (Figs. 2 and 4). Cisplatin activates nu-
clear factor kappa  [thus triggering an increase in proin-
flammatory molecules  and  interleukins  (15)], which  can 
induce PLA2 (59). In addition, cisplatin is able to increase 
production of inflammatory species (15) during renal 
damage. Therefore, a subsequent increase in prostaglan-
dins and thromboxanes, both of which are synthesized 
from AA, is to be expected in the outer medulla (the pref-
erential area of AA synthesis) (60). Accordingly, a striking 
increase in LPI(18:0), a by-product of PLA2 activity on 
PI(18:0/20:4), is observed, especially in the outer medulla. 
Consistent with the observed increase in PI(38:4), these 
observations suggest an increase in turnover of AA for 
eicosanoid synthesis. However, a possible redistribution of 
arachidonate by acyl remodeling, as well as arachidonyl 
turnover, should not be ruled out. Therefore, cilastatin, 
which fully restores both PI(38:4) and LPI(18:0) and tends 
to restore other PI species too,  is able to block cisplatin-
induced apoptosis and its downstream effects. These re-
sults show, for the first time, the underlying process of our 
previous observations (10, 12, 15). Moreover, other phos-
pholipids, such as PC, can also be a source of AA via PLA2. 
In  addition,  PC(36:4)  [mainly  PC(16:0/20:4)  in  kidney] 
(58),  PC(38:4)  [mainly  PC(18:0/20:4)  in  kidney  and 
the main renal PC species] (58), and LPC(18:0) are all 
exclusively increased in the outer medulla after treatment 
with cisplatin and practically restored to control values by 
Fig. 6.  Multivariate analysis shows that protected kidney (treated with both cilastatin and cisplatin) shares lipid features with control sam-
ples, separating from the cisplatin-treated group. PCA 2D score plots are shown for negative-ion mode lipids in cortex (A) and outer medulla 
(C) and positive-ion mode lipids in cortex (B) and outer medulla (D) for ROIs of the four groups of samples: control (red), control+cilastatin 
(green), cisplatin (green), and cisplatin+cilastatin (cyan). The 95% confidence areas are displayed for each group. PLS-DA 2D score plots 
are also shown for control (red) versus cisplatin (green) groups for cortex (E) and medulla (F) lipids detected in positive mode, along with 
the main lipid features ranked by VIP scores (G and H, respectively). A 1.0 cut-off for VIP scores is depicted in G and H.
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cilastatin (Fig. 2). These findings point to the same meta-
bolic activation as that described for PI(38:4).
A number of other LPL species, LPG, LPI, and LPS [cell 
signaling molecules (61)], were also found to be upregu-
lated in the cortex and outer medulla during treatment 
with cisplatin. These proved to be highly discriminating 
variables for cisplatin-damaged kidney versus control tissue 
in PLS-DA. Furthermore, PS undergoes cell membrane ex-
ternalization during apoptotic triggering (62) and induces 
PS-receptor-mediated scavenging of apoptotic cells (63). 
PS can be synthesized de novo from PE (64), thus explain-
ing the cisplatin-induced increase in the cortex in several 
PS species (Fig. 2), which tends to return to control levels 
in the presence of cilastatin.
PG (mostly present in the mitochondrial membrane) is 
a precursor of CLs, which provide essential and functional 
support to proteins involved in mitochondrial respira-
tion (65). CLs are found exclusively in mitochondrial 
membranes and can thus be considered a signature mito-
chondrial lipid class (65). A particularly high density of mi-
tochondria can be found in the distal tubules (66), which 
are mainly located in the medulla. CL in the mitochondrial 
outer membrane provides an anchor for caspase-8, which 
translocates to mitochondria upon Fas receptor activation 
(67). Furthermore, peroxidation of CL seems to precede 
intrinsic apoptotic cell death (65). Accumulation of CL hy-
drolysis products, including AA, has been reported in vivo 
after acute tissue injury (68). Moreover, a decrease in CL 
has been reported in several cell types during apoptosis, 
prior to outer membrane permeabilization (69). Accord-
ing to our results, up to 13 CL species, including the most 
abundant CL  in  kidney, CL(72:8),  followed  by CL(72:7) 
and CL(74:10) (58, 70), proved to be decreased after treat-
ment with cisplatin, mainly in the outer medulla, but also 
in the cortex for 10 of the CL species (Figs. 2 and 4). This 
finding is in agreement with the total cisplatin-induced de-
crease in CL reported in isolated renal mitochondria (71). 
The tendency toward cisplatin-driven reduction observed 
for PUFA phospholipid content (Fig. 5D) might also indi-
rectly indicate lipid oxidation processes, which would be 
prevented by cilastatin. Interestingly, a number of PG spe-
cies, including PG(34:1), the most abundant PG species in 
kidney, were increased in the medulla and cortex as a re-
sult of cisplatin treatment (58). Importantly, PG and CL 
are the few main lipid classes that show no recovery during 
cilastatin cotreatment in some cases, especially in the outer 
medulla (Fig. 2). There is clinical evidence of cisplatin-
induced toxicity in the medullary loop of Henle (72). Con-
sidering that loop of Henle cells have a very high chloride 
concentration owing to cumulative transport through the 
Na+:K+:2Cl– pump, the cisplatin hydrolysis rate can be as-
sumed to be considerably impaired, and, therefore, lower 
drug toxicity would be expected. For this reason, medul-
lary accumulation of protein casts generally explains the 
clinical observations of damage in the loop of Henle (72). 
However, our finding of a reduction in mitochondrial CL, 
Fig. 7. Combined lipid species MALDI imaging for the assessment of renal damage and nephroprotection. MALDI-MSI images in negative-
ion mode are presented for PA(36:1) at m/z 701.5145 (A, D, G, and J) and PI(34:0) at m/z 837.5529 (B, E, H, and K) and the merged image 
for both lipids (C, F, I, and L) for control, control+cilastatin, cisplatin, and cisplatin+cilastatin kidney slices, respectively. Color-scale bars are 
shown for both lipids.
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which is especially visible in the medulla (mainly the loop 
of Henle and distal tubules), suggests direct cisplatin-
induced mitochondrial damage via intrinsic apoptosis in 
the loop of Henle that is not fully reverted by cilastatin and 
that, for some species, remains unchanged.
Of note, most of the lipids that partially recovered after 
cotreatment with cilastatin and cisplatin were found in the 
medulla. Moreover, most of the few unrecovered lipids 
were also found in the medulla. These were mainly mito-
chondrial lipids (CL and PG) (Fig. 2), which could play an 
essential role in energy production, OS, and regulation of 
acute kidney injury. Our observations could be explained 
by direct cisplatin damage not protected by cilastatin that 
specifically inhibits renal DHP-I, which is located mainly in 
the cortex (66). However, most of the changes in lipid dis-
tribution in the cortex and medulla are secondary to cispla-
tin treatment, can be totally discerned with multivariate 
analysis (PCA and PLS-DA) (Fig. 6 and supplemental Figs. 
S3 and S4), and are fully or partially reversed with cilas-
tatin. This finding could be extrapolated to any renal le-
sion mediated by Fas/Fas ligand. Consequently, cilastatin is 
an essential tool for differentiating between lipid changes 
caused by direct interaction with toxic drugs at any level 
and lipid changes secondary to a toxicity-driven insult in 
the proximal tubule. Although our data show that cisplatin-
induced toxicity is mainly restricted to the cortical proxi-
mal tubule, changes in lipid distribution are huge and 
diverse, affecting the whole renal structure. Reversion of 
these changes by cilastatin exemplifies the enormous po-
tential of this drug for improving renal function and di-
minishing structural changes.
The PCA/PLS-DA classification of the groups may be 
correlated with renal function and could be used as an al-
ternative model for the assessment of nephrotoxicity and 
nephroprotection during therapy with cisplatin. This is 
clear when comparing merged lipid images from different 
groups with different distribution patterns. MSI enables 
hundreds of lipids to be monitored in a single analysis, 
and, considering the heterogeneous distribution of lipids 
in kidney, a plethora of possible combinations for visualiz-
ing kidney function status is available, with 31 lipid species 
showing totally recovered renal distribution compared 
with controls during protection from cisplatin-induced re-
nal damage with cilastatin (Fig. 2).
In conclusion, MSI is presented as a powerful research 
tool  for  studying  nephrotoxicity  and  kidney  diseases  
in animal models and for the development of novel 
nephroprotective drugs, especially those targeting lipid 
rafts. MSI enables simultaneous understanding of com-
plex processes, such as changes in mitochondrial struc-
ture and cell membrane phenomena related to apoptosis 
in acute kidney injury. Moreover, it provides straightfor-
ward information on the structural interconnection be-
tween the cortex and the medulla during renal damage 
and its recovery.
The authors thank José Manuel Lara for tissue sectioning and 
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